ClinicalTrials.gg
CompletedNCT05993299Updated Sep 2, 2026Results posted

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

A Phase 2 interventional study of Letetresgene autoleucel and Cyclophosphamide in Neoplasms, sponsored by USWM, LLC (dba US WorldMeds). Completed at 38 sites in 7 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Dec 2019, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Study summary

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Adoptive T-cell therapy
  • Letetresgene autoleucel
  • Lete-cel
  • GSK3377794
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 7 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be greater than or equal to 10 years of age on the day of signing .
  • Participant scheduled to receive clinical drug product supply must also weigh ≥40 kg
  • Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles by a designated central laboratory
  • Participant's tumor is positive for NY-ESO-1 expression by a designated central laboratory.
  • Participant has a diagnosis of synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS)
  • Performance status: dependent on age - Lansky > 60, > 60, Eastern
  • Cooperative Oncology Group 0-1.
  • Participant must have adequate organ function and blood cell counts, within 7 days prior to leukapheresis.
  • At time of treatment, participant has according to v1.1.
  • Male or female. requirements will apply at the time of leukapheresis and treatment.
  • Consultation for prior history per protocol specifications.

Exclusion criteria

Exclusion Criteria:

  • Central nervous system .
  • Any other prior that is not in complete remission.
  • systemic illness (.(Serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction, that in the judgment of the Investigator would compromise the participant's ability to tolerate protocol therapy or significantly increase the risk of complications)
  • Prior or active demyelinating disease.
  • History of chronic or recurrent (within the last year prior to leukapheresis) severe or immune mediated disease (e.g. Crohn's disease, systemic lupus) requiring or other treatments.
  • Previous treatment with genetically engineered NY-ESO-1-specific T cells.
  • Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.
  • Prior gene therapy using an integrating vector.
  • Previous hematopoietic stem cell transplant.
  • for prior radiotherapy and systemic chemotherapy must be followed.
  • Participant had major surgery in less than or equal to 28 days of first dose of study intervention.
  • Prior radiation exceeds protocol specified limits.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Letetresgene autoleucel

    Drug: Letetresgene autoleucel · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 relative to the total number of participants in the analysis population. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline). 95% CI is based on Clopper-Pearson exact confidence interval.

    Time frame: Up to approximately 36 months

Secondary outcomes

  1. Time to Response (TTR)

    Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline).

    Time frame: Up to approximately 54 months

  2. Duration of Response (DOR)

    Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease as assessed by local investigators, or death among participants with a confirmed response per RECIST 1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline).

    Time frame: Up to approximately 54 months

  3. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) with a minimal 12 weeks (84 days ± 7 day window) duration relative to the total number of participants within the analysis population at the time of primary analysis as determined by local investigators per RECIST v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline). SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. The disease progression (PD) is defined as the date of radiological disease progression based on imaging data per RECIST v1.1. 95% CI is based on Clopper-Pearson exact confidence interval.

    Time frame: Up to approximately 36 months

  4. Progression Free Survival (PFS)

    PFS is defined as the interval of time between from the date of T-cell infusion to the earliest date of radiological progression of disease (PD) as assessed by local investigator per RECIST v1.1, or death due to any cause. The PD is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

    Time frame: Up to approximately 54 months

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.

    Time frame: Up to approximately 54 months

  6. Number of Participants With AEs of Special Interest (AESIs)

    An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. AESIs included cytokine release syndrome (CRS), hematopoietic cytopenias (including pancytopenia and aplastic anemia), graft vs host disease (GVHD), ICANS, Guillain-Barre syndrome, treatment-related inflammatory response at tumor site(s), and neutropenia Grade 4 lasting ≥28 days.

    Time frame: Up to approximately 54 months

  7. Number of Participants With TEAEs and TESAEs by Severity

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. AEs and SAEs were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences; Grade 5- Death related to AE.

    Time frame: Up to approximately 54 months

  8. Number of Participants With AESIs by Severity

    An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. AESIs included cytokine release syndrome (CRS), hematopoietic cytopenias (including pancytopenia and aplastic anemia), graft vs host disease (GVHD), ICANS, Guillain-Barre syndrome, treatment-related inflammatory response at tumor site(s), and neutropenia Grade 4 lasting ≥28 days.

    Time frame: Up to approximately 54 months

  9. Percentage of Participants With Replication Competent Lentivirus (RCL) Positive

    RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).

    Time frame: Up to approximately 54 months

  10. Instances of Insertional Oncogenesis (IO)

    Instances of Insertional Oncogenesis (IO) was summarized descriptively.

    Time frame: Up to approximately 54 months

  11. Maximum Transgene Expansion (Cmax)

    Cmax was defined as maximum observed persistence, determined directly from the persistence-time data. Blood samples were collected for PK analysis.

    Time frame: Day 1 to Day 14

  12. Time to Cmax (Tmax)

    Tmax was defined as time to reach Cmax, determined directly from the persistence-time data. Blood samples were collected for PK analysis.

    Time frame: Day 1 to Day 14

  13. Area Under the Time Curve From Zero to Time 28 Days (AUC[0-28])

    Area under the persistence-time curve from time zero to Day 28. Blood samples were collected for PK analysis.

    Time frame: Up to 28 days

07

Results

Posted Oct 16, 2023

Participant flow

Participant flow — Overall Study
MilestoneLetetresgene Autoleucel (Lete-cel)
Started7
Received t cell infusion5
Completed1
Not completed6
Withdrew: Did not meet treatment eligibility criteria2
Withdrew: Ongoing4

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 relative to the total number of participants in the analysis population. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline). 95% CI is based on Clopper-Pearson exact confidence interval.

Time frame:
Up to approximately 36 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsLetetresgene Autoleucel (Lete-cel)
Overall Response Rate (ORR)80 (28.4 to 99.5)
SecondaryTime to Response (TTR)

Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline).

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR)

Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease as assessed by local investigators, or death among participants with a confirmed response per RECIST 1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline).

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) with a minimal 12 weeks (84 days ± 7 day window) duration relative to the total number of participants within the analysis population at the time of primary analysis as determined by local investigators per RECIST v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent change from baseline). SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. The disease progression (PD) is defined as the date of radiological disease progression based on imaging data per RECIST v1.1. 95% CI is based on Clopper-Pearson exact confidence interval.

Time frame:
Up to approximately 36 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsLetetresgene Autoleucel (Lete-cel)
Disease Control Rate (DCR)80.0 (28.4 to 99.5)
SecondaryProgression Free Survival (PFS)

PFS is defined as the interval of time between from the date of T-cell infusion to the earliest date of radiological progression of disease (PD) as assessed by local investigator per RECIST v1.1, or death due to any cause. The PD is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With AEs of Special Interest (AESIs)

An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. AESIs included cytokine release syndrome (CRS), hematopoietic cytopenias (including pancytopenia and aplastic anemia), graft vs host disease (GVHD), ICANS, Guillain-Barre syndrome, treatment-related inflammatory response at tumor site(s), and neutropenia Grade 4 lasting ≥28 days.

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs and TESAEs by Severity

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. AEs and SAEs were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences; Grade 5- Death related to AE.

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With AESIs by Severity

An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. AESIs included cytokine release syndrome (CRS), hematopoietic cytopenias (including pancytopenia and aplastic anemia), graft vs host disease (GVHD), ICANS, Guillain-Barre syndrome, treatment-related inflammatory response at tumor site(s), and neutropenia Grade 4 lasting ≥28 days.

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Replication Competent Lentivirus (RCL) Positive

RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryInstances of Insertional Oncogenesis (IO)

Instances of Insertional Oncogenesis (IO) was summarized descriptively.

Time frame:
Up to approximately 54 months

Results for this outcome have not been posted.

SecondaryMaximum Transgene Expansion (Cmax)

Cmax was defined as maximum observed persistence, determined directly from the persistence-time data. Blood samples were collected for PK analysis.

Time frame:
Day 1 to Day 14
Reported as:
Geometric mean · Copies per microgram genomic DNA
Maximum Transgene Expansion (Cmax)
Copies per microgram genomic DNALetetresgene Autoleucel (Lete-cel)
Maximum Transgene Expansion (Cmax)119701.64 ± 68.267
SecondaryTime to Cmax (Tmax)

Tmax was defined as time to reach Cmax, determined directly from the persistence-time data. Blood samples were collected for PK analysis.

Time frame:
Day 1 to Day 14
Reported as:
Median · Days
Time to Cmax (Tmax)
DaysLetetresgene Autoleucel (Lete-cel)
Time to Cmax (Tmax)6.90 (1.9 to 13.6)
SecondaryArea Under the Time Curve From Zero to Time 28 Days (AUC[0-28])

Area under the persistence-time curve from time zero to Day 28. Blood samples were collected for PK analysis.

Time frame:
Up to 28 days
Reported as:
Geometric mean · Days*copies per microgram genomic DNA
Area Under the Time Curve From Zero to Time 28 Days (AUC[0-28])
Days*copies per microgram genomic DNALetetresgene Autoleucel (Lete-cel)
Area Under the Time Curve From Zero to Time 28 Days (AUC[0-28])1911782.96 ± 53.709

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected maximum up to approximately 36 months. Data collection is still ongoing and additional results will be provided after study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letetresgene Autoleucel (Lete-cel)1/7 (14.3%)4/7 (57.1%)5/7 (71.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLetetresgene Autoleucel (Lete-cel)
Gastrointestinal haemorrhageGastrointestinal disorders1/7
NauseaGastrointestinal disorders1/7
Small intestinal obstructionGastrointestinal disorders1/7
VomitingGastrointestinal disorders1/7
Cytokine release syndromeImmune system disorders1/7
Graft versus host diseaseImmune system disorders1/7
AnaemiaBlood and lymphatic system disorders1/7
Radiation pneumonitisInjury, poisoning and procedural complications1/7
Weight decreasedInvestigations1/7
DehydrationMetabolism and nutrition disorders1/7
Most frequent other events
Showing 10 of 68
Most frequent other events
EventLetetresgene Autoleucel (Lete-cel)
Cytokine release syndromeImmune system disorders4/7
FatigueGeneral disorders4/7
COVID-19Infections and infestations3/7
Alanine aminotransferase increasedInvestigations3/7
ConstipationGastrointestinal disorders3/7
Gastrooesophageal reflux diseaseGastrointestinal disorders3/7
NauseaGastrointestinal disorders3/7
DyspnoeaRespiratory, thoracic and mediastinal disorders3/7
Aspartate aminotransferase increasedInvestigations2/7
Blood fibrinogen decreasedInvestigations2/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Letetresgene Autoleucel (Lete-cel)
Mean49.4 ± 16.70
Age, Customized
Age, Customized(Participants)Letetresgene Autoleucel (Lete-cel)
<=18 years1
19-64 years6
Sex: Female, Male
Sex: Female, Male(Participants)Letetresgene Autoleucel (Lete-cel)
Female5
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Letetresgene Autoleucel (Lete-cel)
Hispanic or Latino3
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Letetresgene Autoleucel (Lete-cel)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Letetresgene Autoleucel (Lete-cel)
Canada1
Netherlands2
United Kingdom1
United States3
08

Study locations

38 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford Hospital and Clinics
    Stanford, California 94305, United States
  • Sarah Cannon Research Institute
    Denver, Colorado 80218, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Iowa College of Medicine
    Iowa City, Iowa 52242-1009, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Minnesota Oncology Hematology
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering cancer center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Ohio State University-Columbus
    Columbus, Ohio 43210, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh, Hillman Cancer centre
    Pittsburgh, Pennsylvania 15232, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • University Of Texas Southwestern Medical Center
    Dallas, Texas 75390-8565, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9063, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109-1024, United States
  • Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • CIUSSS de L'Est-De-Lile-De-Montreal
    Montreal, Quebec H1T 2M4, Canada
  • Princess Margaret Cancer Centre
    Toronto, M5G 2M9, Canada
  • Centre Léon Bérard
    Lyon, 69373, France
  • CHU de Bordeaux GH Sud Hôpital Haut Lévêque
    Pessac, 33604, France
  • Fondazione IRCCS Instituto Nazionale Dei Tumori
    Milan, 20133, Italy
  • Ircss Istituto Clinico Humanitas
    Romano di Lombardia, 20089, Italy
  • The Netherlands Cancer Institute
    Amsterdam, 1066 CX, Netherlands
  • Hospital Santa Creu Y Sant Pau
    Barcelona, 08025, Spain
  • Ico Duran y Reynals l'Hospitalet de Llobrega
    Hospitalet de Llobregat, Barcelona, 08907, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Virgen Del Rocio
    Seville, 41013, Spain
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • University College Hospital-London
    London, WC1E 6AG, United Kingdom
  • Christie Hospital NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Oct 2022, 33 months.

Results were first posted in Oct 2023, 1 year after primary completion.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 33 months is below that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 15, 2023
StartActual
Dec 31, 2019
Primary completionActual
Oct 12, 2022
CompletionActual
Mar 17, 2026
Results first posted
Oct 16, 2023
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05993299
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
Aug 15, 2023
Start date
Dec 31, 2019
Primary completion
Oct 12, 2022
Completion
Mar 17, 2026
Results posted
Oct 16, 2023
Last update
Sep 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letetresgene autoleucel

Start the discussion